Evidence map›Paper›PMID 33478322›Full record

ReviewJournal of dental research2021

Harnessing Dental Stem Cell Immunoregulation Using Cell-Laden Biomaterials.

S Pouraghaei Sevari, S Ansari, C Chen, A Moshaverinia

Open access · greenAbstract readReview
In one paragraph

Review in Journal of dental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. [Advances in Molecular Regulatory Mechanisms of Jaw Repair and Reconstruction].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Stem cells and common biomaterials in dentistry: a review study.Journal of materials science. Materials in medicine · 2022
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

S Pouraghaei SevariWeintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-0810-2573
S AnsariWeintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.
C ChenDepartment of Oral and Maxillofacial Surgery and Pharmacology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
A MoshaveriniaWeintraub Center for Reconstructive Biotechnology, Division of Advanced Prosthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · USUniversity of Pennsylvania · US

Funding

FAS Controls Exosome-Mediated miRNA Transfer in MSC-Based TherapyR00DE025915 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · 2019 to 2021
$732k
Epigenetic Regulation of Mesenchymal Stem Cell Transplantation in AgingR03DE028026 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · 2019 to 2020
$324k
The role of elasticity of biomaterials on the stem cell-host immune cell interplayR03DE029876 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MOSHAVERINIA, ALIREZA · 2020 to 2021
$312k
FAS Controls Exosome-Mediated miRNA Transfer in MSC-Based TherapyK99DE025915 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · 2016 to 2017
$142k
NIDCR NIH HHS K99 DE025915NIDCR NIH HHS R00 DE025915NIDCR NIH HHS R03 DE028026NIDCR NIH HHS R03 DE029876
6 · The paper itself

Abstract

Successful tissue engineering therapies rely on the appropriate selection of the cell source, biomaterial, and regulatory factors. To be applied in a wide range of clinical applications, the ideal cell source needs to be easily accessible and abundant. Human orofacial tissues and teeth harbor several populations of mesenchymal stem cells (MSCs) with self-renewal and multilineage differentiation capabilities. The ease of access, relative abundance, and minimally invasive isolation procedures needed to harvest most types of the dental-derived MSCs render them a promising cell source for tissue engineering applications. A growing body of evidence has reported the profound immunoregulatory potential of dental-derived MSCs as compared with their bone marrow counterparts. Biomaterials can act as a physical barrier protecting the MSCs from the invasion of the immune system by hindering penetration of proinflammatory cells/cytokines, leading to higher viability of the encapsulated MSCs and improved tissue regeneration. Besides their protective capabilities, biomaterials can actively contribute to the immunoregulatory potential of the MSCs through their physical and chemical properties, including porosity and elasticity. However, despite recent advancement, the therapeutic capability of biomaterials to regulate the MSC-host immune system crosstalk and the mechanism underlying this immunoregulation has been poorly understood. It has been reported that biomaterials can regulate the viability and determine the fate of the encapsulated MSCs through modulation of the NF-kB pathway and the caspase-3 and caspase-8 proapoptotic cascades. Additionally, the physiomechanical properties of the encapsulating biomaterial have been shown to modulate clustering of TNF-α receptors on the encapsulated MSCs while regulating the production of anti-inflammatory factors such as indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE

Indexed as

Biocompatible MaterialsMesenchymal Stem CellsCell DifferentiationHumansImmunomodulationTissue EngineeringBiocompatible Materialsbiomedical materialsdental-derived mesenchymal cellsimmune cell-stem cell crosstalkimmunoregulationphysiomechanical propertiestissue engineering

Identifiers

PMID33478322
PMCPMC8142087
OpenAlexW3125297057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.